However, alternative receptor tyrosine kinases (EGFR, MET, HER2), post-translational processes (such as SUMOylation), IGF1R-EMT-independent pathways, and cancer–cell microenvironment interactions suggest that current preclinical models do not fully recapitulate the complex clinical scenario. The gene discussed is EGFR; the disease is cancer.